Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-58183-w
Abstract: Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with CCNE1-amplification are often resistant to standard treatment and represent an unmet clinical need. Synthetic-lethal screening identified loss of the CDK1 regulator, PKMYT1, as synthetically lethal with CCNE1-amplification.… read more here.
Keywords: ccne1; ovarian endometrial; pkmyt1; endometrial cancers ... See more keywords
Abstract A026: Discovery of potent and selective CDK2 molecule glue degraders for the treatment of HR+/HER2- breast cancer, and CCNE1 amplified tumors
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-a026
Abstract: The Cyclin-Dependent Kinase 2 (CDK2) is a key oncology target and promotes cell cycle progression by binding to its cyclin binding partners, especially, Cyclin E (CCNE1). The activated CCNE1/CDK2 complex phosphorylates RB and promotes cellular… read more here.
Keywords: glue degraders; cancer; cdk2; breast ... See more keywords